Evidence map›Paper›PMID 39183323›Full record

ReviewBiomarker research2024

Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment.

Tongtao Zhuang, Shenrong Wang, Xiaoqian Yu, Xiaoyun He, Hongbin Guo, Chunlin Ou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tongtao Zhuang *Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Shenrong Wang *Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xiaoqian YuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xiaoyun HeDepartments of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Hongbin Guo *Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. ghb_0113@sina.com.
Chunlin Ou *Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. ouchunlin@csu.edu.cn.

Funding

Central South University Innovation-Driven Research Programme 2023CXQD075National Natural Science Foundation of China 82373062Natural Science Foundation of Hunan Province 2022JJ40784Natural Science Foundation of Hunan Province 2024JJ7636Outstanding Youth Foundation of Hunan Provincial Natural Science Foundation of China 2022JJ20098
6 · The paper itself

Abstract

Platelets are a significant component of the cell population in the tumour microenvironment (TME). Platelets influence other immune cells and perform cross-talk with tumour cells, playing an important role in tumour development. Extracellular vesicles (EVs) are small membrane vesicles released from the cells into the TME. They can transfer biological information, including proteins, nucleic acids, and metabolites, from secretory cells to target receptor cells. This process affects the progression of various human diseases, particularly cancer. In recent years, several studies have demonstrated that platelet-derived extracellular vesicles (PEVs) can help regulate the malignant biological behaviours of tumours, including malignant proliferation, resistance to cell death, invasion and metastasis, metabolic reprogramming, immunity, and angiogenesis. Consequently, PEVs have been identified as key regulators of tumour progression. Therefore, targeting PEVs is a potential strategy for tumour treatment. Furthermore, the extensive use of nanomaterials in medical research has indicated that engineered PEVs are ideal delivery systems for therapeutic drugs. Recent studies have demonstrated that PEV engineering technologies play a pivotal role in the treatment of tumours by combining photothermal therapy, immunotherapy, and chemotherapy. In addition, aberrant changes in PEVs are closely associated with the clinicopathological features of patients with tumours, which may serve as liquid biopsy markers for early diagnosis, monitoring disease progression, and the prognostic assessment of patients with tumours. A comprehensive investigation into the role and potential mechanisms of PEVs in tumourigenesis may provide novel diagnostic biomarkers and potential therapeutic strategies for treating human tumours.

Indexed as

EngineeringExtracellular vesiclesImmunotherapyLiquid biopsyPlateletsTumour microenvironment

Identifiers

PMID39183323
PMCPMC11346179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.